View Financial HealthSprint Bioscience 배당 및 자사주 매입배당 기준 점검 0/6Sprint Bioscience 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-6.2%자사주 매입 수익률총 주주 수익률-6.2%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 10Sprint Bioscience AB (publ), Annual General Meeting, May 13, 2026Sprint Bioscience AB (publ), Annual General Meeting, May 13, 2026, at 15:00 W. Europe Standard Time. Location: sprint biosciences premises at novum, halsovagen 7, 141 57 huddinge, Sweden공시 • Mar 18Sprint Bioscience AB (publ) Presents New Preclinical Data On Dcps Program At The Aacr Annual MeetingSprint Bioscience AB (publ) announced that new preclinical data from the company’s DCPS program will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place on April 17, 2026, in San Diego, USA. The poster presentation summarizes new research findings supporting DCPS inhibition as a valid therapeutic strategy for patients with acute myeloid leukemia (AML). The results deepen the scientific understanding of DCPS biology and highlights its potential to improve patient stratification in AML. The poster “Integrated FHIT and IDH2 biomarkers predict synthetic lethal response to DCPS inhibition in acute myeloid leukemia” will be presented by Madhurendra Singh, Associate Principal Scientist at Sprint Bioscience.공시 • Apr 05Sprint Bioscience AB (publ), Annual General Meeting, May 07, 2025Sprint Bioscience AB (publ), Annual General Meeting, May 07, 2025, at 15:00 W. Europe Standard Time. Location: at sprint bioscience`s, premises, at novum Sweden공시 • Dec 18Sprint Bioscience AB (Publ) Adds New Cancer Drug Program to PortfolioSprint Bioscience AB (publ) announced that the company is broadening its portfolio with a drug development program for the treatment of acute myeloid leukemia (AML). The program targets the decapping scavenger enzyme (DCPS), a target protein that has been validated both in scientific literature and by Sprint Bioscience in collaboration with Associate Professor Julian Walfridsson at Karolinska Institutet. The initiation of Sprint Bioscience's DCPS program is part of the company's strategy to capitalize on its platform for small-molecule drug discovery to broaden the portfolio in the cancer area and to bring more opportunities for future licensing deals. The DCPS program focuses on a target protein that degrades a metabolite resulting from the processing of mRNA. Both small-molecule inhibition and genetic knock-down of DCPS affects the differentiation and proliferation of several AML cell lines as well as patient-derived samples. Furthermore, healthy tissue seems to be insensitive to DCPS inhibition, indicating that DCPS inhibitors could offer a safe and effective treatment option for AML patients. Sprint Bioscience has also identified biomarkers to predict response to DCPS inhibition, enabling patient selection and clinical success for patients with unmet therapeutic needs. AML is a severe type of blood cancer. The Global Burden of Disease study estimates that about 140,000 people around the world are diagnosed with AML on a yearly basis. There is an urgent medical need to identify safe and effective therapies to improve treatment outcomes. Sprint Bioscience's portfolio now consists of six internal drug development programs (five of which are in cancer) and one program that has been licensed to Day One Biopharmaceuticals.Reported Earnings • Nov 01Third quarter 2024 earnings released: kr0.075 loss per share (vs kr0.41 profit in 3Q 2023)Third quarter 2024 results: kr0.075 loss per share (down from kr0.41 profit in 3Q 2023). Revenue: kr14.8m (down 63% from 3Q 2023). Net loss: kr5.21m (down 118% from profit in 3Q 2023). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 16Full year 2023 earnings released: kr0.006 loss per share (vs kr1.43 loss in FY 2022)Full year 2023 results: kr0.006 loss per share (improved from kr1.43 loss in FY 2022). Revenue: kr54.3m (up kr54.2m from FY 2022). Net loss: kr438.0k (loss narrowed 99% from FY 2022). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: kr0.41 (vs kr0.33 loss in 3Q 2022)Third quarter 2023 results: EPS: kr0.41 (up from kr0.33 loss in 3Q 2022). Revenue: kr41.2m (up kr41.2m from 3Q 2022). Net income: kr28.6m (up kr41.9m from 3Q 2022). Profit margin: 70% (up from net loss in 3Q 2022). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 28Second quarter 2023 earnings released: kr0.17 loss per share (vs kr0.45 loss in 2Q 2022)Second quarter 2023 results: kr0.17 loss per share (improved from kr0.45 loss in 2Q 2022). Net loss: kr11.7m (loss narrowed 35% from 2Q 2022). Revenue is forecast to grow 51% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.Buying Opportunity • Jul 24Now 36% undervalued after recent price dropOver the last 90 days, the stock is down 26%. The fair value is estimated to be €0.036, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 31% over the last 3 years. Earnings per share has grown by 35%.Buying Opportunity • Jun 17Now 29% undervaluedOver the last 90 days, the stock is up 14%. The fair value is estimated to be €0.038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 31% over the last 3 years. Earnings per share has grown by 35%.Buying Opportunity • May 31Now 24% undervaluedOver the last 90 days, the stock is up 9.4%. The fair value is estimated to be €0.052, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 31% over the last 3 years. Earnings per share has grown by 35%.Buying Opportunity • Mar 14Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 8.6%. The fair value is estimated to be €0.038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 22% over the last 3 years. Earnings per share has grown by 31%.Reported Earnings • Feb 17Full year 2022 earnings released: kr1.43 loss per share (vs kr0.85 loss in FY 2021)Full year 2022 results: kr1.43 loss per share (further deteriorated from kr0.85 loss in FY 2021). Net loss: kr60.2m (loss widened 140% from FY 2021). Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe.Reported Earnings • Oct 30Third quarter 2022 earnings released: kr0.33 loss per share (vs kr0.54 profit in 3Q 2021)Third quarter 2022 results: kr0.33 loss per share (down from kr0.54 profit in 3Q 2021). Net loss: kr13.3m (down 176% from profit in 3Q 2021). Revenue is forecast to grow 79% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany.Reported Earnings • Aug 25Second quarter 2022 earnings released: kr0.45 loss per share (vs kr0.60 loss in 2Q 2021)Second quarter 2022 results: kr0.45 loss per share. Revenue: kr24.0k (up 100% from 2Q 2021). Net loss: kr17.9m (loss widened 29% from 2Q 2021).Reported Earnings • May 13First quarter 2022 earnings released: kr0.36 loss per share (vs kr0.65 loss in 1Q 2021)First quarter 2022 results: kr0.36 loss per share. Revenue: kr53.0k (down 87% from 1Q 2021). Net loss: kr14.2m (loss widened 3.7% from 1Q 2021).공시 • May 08Sprint Bioscience Launches NIMA at BIO InternationalSprint Bioscience announced its latest development project NIMA. Now the company chooses to shed some more light on the program, revealing the target protein. The official launch will be at BIO International, which this year will be held in San Diego June 13-16.Board Change • Apr 27High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Director Rune Nordlander is the most experienced director on the board, commencing their role in 2010. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 18Full year 2021 earnings released: kr0.85 loss per share (vs kr2.55 loss in FY 2020)Full year 2021 results: kr0.85 loss per share (up from kr2.55 loss in FY 2020). Revenue: kr35.0m (up 83% from FY 2020). Net loss: kr25.1m (loss narrowed 41% from FY 2020). Over the next year, revenue is expected to shrink by 5.8% compared to a 44% growth forecast for the pharmaceuticals industry in Germany.Reported Earnings • Feb 17Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: kr0.85 loss per share (up from kr2.55 loss in FY 2020). Revenue: kr35.1m (up 83% from FY 2020). Net loss: kr25.1m (loss narrowed 41% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is expected to shrink by 5.9% compared to a 59% growth forecast for the pharmaceuticals industry in Germany.Reported Earnings • Oct 29Third quarter 2021 earnings released: EPS kr0.54 (vs kr0.36 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr33.9m (up 399% from 3Q 2020). Net income: kr17.6m (up kr23.6m from 3Q 2020). Profit margin: 52% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue.공시 • Sep 08Sprint Bioscience AB (publ) Adds New Cancer Drug Program to its Project PortfolioSprint Bioscience AB (publ) announces that the company is broadening its pipeline with an additional drug program for the treatment of solid tumors. The program goes by the program name NIMA and aims to develop drugs to inhibit a naturally occurring protein that is associated with poor survival in several different forms of cancer. An important aspect of the development of a tumor is that the cancer cells can affect their environment to facilitate the growth of the tumor. This environment is called the tumor microenvironment and differs from the environment around the healthy cells in the body. The ability of cancer cells to reprogram the healthy cells present in the tumor facilitates tumor growth and can inhibit the body's immune system. The NIMA program focuses on a target protein that produces metabolites that are important for this reprogramming of the tumor's microenvironment. Sprint Bioscience develops inhibitors of this target protein to restore balance and thereby prevent the growth of cancer cells while increasing the immune system's ability to attack them. High levels of the current target protein have been found in tumors from, amongst others, ovarian cancer, breast cancer, and colorectal cancer. Patients with high levels of this protein have a poorer prognosis.Reported Earnings • Aug 18Second quarter 2021 earnings released: kr0.60 loss per share (vs kr1.01 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: kr12.0k (down 100% from 2Q 2020). Net loss: kr13.9m (loss widened 11% from 2Q 2020).Reported Earnings • May 14First quarter 2021 earnings released: kr0.65 loss per share (vs kr0.79 loss in 1Q 2020)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: kr408.0k (down 93% from 1Q 2020). Net loss: kr13.7m (loss widened 40% from 1Q 2020).공시 • Apr 10Sprint Bioscience AB (publ) announced that it has received SEK 20.713701 million in fundingSprint Bioscience AB (publ) (OM:SPRINT) announced a private placement of 4,061,510 shares at an issue price SEK 5.10 per share for gross proceeds of SEK 20,713,701 on April 8, 2021. The transaction included participation from new and existing investors.Executive Departure • Mar 03Interim Chief Executive Officer Charlotte Leife has left the companyOn the 1st of March, Charlotte Leife's tenure as Interim Chief Executive Officer of the company ended after less than a year in the role. We don't have any record of a personal shareholding under Charlotte's name. Charlotte is the only executive to leave the company over the last 12 months. Under Charlotte's leadership, the company delivered a total shareholder return of -1.3%.공시 • Feb 26Sprint Bioscience AB (publ) Appoints Erik Kinnman as New CEO in Place of Charlotte LeifeSprint Bioscience AB (publ) announced that Erik Kinnman has been appointed as new CEO of the company. He has 25 years of experience from leading positions in the pharmaceutical and biotechnology industry. Erik Kinnman will take up the role on March 1 and succeed Charlotte Leife, who has been acting CEO since September 1, 2021. Erik Kinnman was between 2016 and January 2021 CEO of Abliva AB (formerly Neurovive). Prior to that, he held senior positions at AstraZeneca and SOBI and was also active as a financial analyst at Danske Bank.Is New 90 Day High Low • Feb 21New 90-day low: €0.63The company is down 17% from its price of €0.76 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period.Analyst Estimate Surprise Post Earnings • Feb 20Revenue beats expectationsRevenue exceeded analyst estimates by 13%. Over the next year, revenue is forecast to grow 62%, compared to a 50% growth forecast for the Biotechs industry in Germany.Reported Earnings • Feb 19Full year 2020 earnings released: kr2.02 loss per share (vs kr1.92 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: kr19.6m (down 42% from FY 2019). Net loss: kr42.8m (loss widened 99% from FY 2019).Is New 90 Day High Low • Feb 03New 90-day low: €0.68The company is down 10.0% from its price of €0.76 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period.Reported Earnings • Nov 02Third quarter 2020 earnings released: kr0.36 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: kr6.79m (up 55% from 3Q 2019). Net loss: kr5.99m (loss narrowed 17% from 3Q 2019).지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 5JA1 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 5JA1 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Sprint Bioscience 배당 수익률 vs 시장5JA1의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (5JA1)n/a시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.5%업계 평균 (Biotechs)2.2%분석가 예측 (5JA1) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 5JA1 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 5JA1 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 5JA1 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 5JA1 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 16:03종가2026/05/21 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Sprint Bioscience AB (publ)는 2명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Siri LadowDanske BankFredrik ThorRedeye
공시 • Apr 10Sprint Bioscience AB (publ), Annual General Meeting, May 13, 2026Sprint Bioscience AB (publ), Annual General Meeting, May 13, 2026, at 15:00 W. Europe Standard Time. Location: sprint biosciences premises at novum, halsovagen 7, 141 57 huddinge, Sweden
공시 • Mar 18Sprint Bioscience AB (publ) Presents New Preclinical Data On Dcps Program At The Aacr Annual MeetingSprint Bioscience AB (publ) announced that new preclinical data from the company’s DCPS program will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place on April 17, 2026, in San Diego, USA. The poster presentation summarizes new research findings supporting DCPS inhibition as a valid therapeutic strategy for patients with acute myeloid leukemia (AML). The results deepen the scientific understanding of DCPS biology and highlights its potential to improve patient stratification in AML. The poster “Integrated FHIT and IDH2 biomarkers predict synthetic lethal response to DCPS inhibition in acute myeloid leukemia” will be presented by Madhurendra Singh, Associate Principal Scientist at Sprint Bioscience.
공시 • Apr 05Sprint Bioscience AB (publ), Annual General Meeting, May 07, 2025Sprint Bioscience AB (publ), Annual General Meeting, May 07, 2025, at 15:00 W. Europe Standard Time. Location: at sprint bioscience`s, premises, at novum Sweden
공시 • Dec 18Sprint Bioscience AB (Publ) Adds New Cancer Drug Program to PortfolioSprint Bioscience AB (publ) announced that the company is broadening its portfolio with a drug development program for the treatment of acute myeloid leukemia (AML). The program targets the decapping scavenger enzyme (DCPS), a target protein that has been validated both in scientific literature and by Sprint Bioscience in collaboration with Associate Professor Julian Walfridsson at Karolinska Institutet. The initiation of Sprint Bioscience's DCPS program is part of the company's strategy to capitalize on its platform for small-molecule drug discovery to broaden the portfolio in the cancer area and to bring more opportunities for future licensing deals. The DCPS program focuses on a target protein that degrades a metabolite resulting from the processing of mRNA. Both small-molecule inhibition and genetic knock-down of DCPS affects the differentiation and proliferation of several AML cell lines as well as patient-derived samples. Furthermore, healthy tissue seems to be insensitive to DCPS inhibition, indicating that DCPS inhibitors could offer a safe and effective treatment option for AML patients. Sprint Bioscience has also identified biomarkers to predict response to DCPS inhibition, enabling patient selection and clinical success for patients with unmet therapeutic needs. AML is a severe type of blood cancer. The Global Burden of Disease study estimates that about 140,000 people around the world are diagnosed with AML on a yearly basis. There is an urgent medical need to identify safe and effective therapies to improve treatment outcomes. Sprint Bioscience's portfolio now consists of six internal drug development programs (five of which are in cancer) and one program that has been licensed to Day One Biopharmaceuticals.
Reported Earnings • Nov 01Third quarter 2024 earnings released: kr0.075 loss per share (vs kr0.41 profit in 3Q 2023)Third quarter 2024 results: kr0.075 loss per share (down from kr0.41 profit in 3Q 2023). Revenue: kr14.8m (down 63% from 3Q 2023). Net loss: kr5.21m (down 118% from profit in 3Q 2023). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 16Full year 2023 earnings released: kr0.006 loss per share (vs kr1.43 loss in FY 2022)Full year 2023 results: kr0.006 loss per share (improved from kr1.43 loss in FY 2022). Revenue: kr54.3m (up kr54.2m from FY 2022). Net loss: kr438.0k (loss narrowed 99% from FY 2022). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.
Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: kr0.41 (vs kr0.33 loss in 3Q 2022)Third quarter 2023 results: EPS: kr0.41 (up from kr0.33 loss in 3Q 2022). Revenue: kr41.2m (up kr41.2m from 3Q 2022). Net income: kr28.6m (up kr41.9m from 3Q 2022). Profit margin: 70% (up from net loss in 3Q 2022). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 28Second quarter 2023 earnings released: kr0.17 loss per share (vs kr0.45 loss in 2Q 2022)Second quarter 2023 results: kr0.17 loss per share (improved from kr0.45 loss in 2Q 2022). Net loss: kr11.7m (loss narrowed 35% from 2Q 2022). Revenue is forecast to grow 51% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.
Buying Opportunity • Jul 24Now 36% undervalued after recent price dropOver the last 90 days, the stock is down 26%. The fair value is estimated to be €0.036, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 31% over the last 3 years. Earnings per share has grown by 35%.
Buying Opportunity • Jun 17Now 29% undervaluedOver the last 90 days, the stock is up 14%. The fair value is estimated to be €0.038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 31% over the last 3 years. Earnings per share has grown by 35%.
Buying Opportunity • May 31Now 24% undervaluedOver the last 90 days, the stock is up 9.4%. The fair value is estimated to be €0.052, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 31% over the last 3 years. Earnings per share has grown by 35%.
Buying Opportunity • Mar 14Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 8.6%. The fair value is estimated to be €0.038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 22% over the last 3 years. Earnings per share has grown by 31%.
Reported Earnings • Feb 17Full year 2022 earnings released: kr1.43 loss per share (vs kr0.85 loss in FY 2021)Full year 2022 results: kr1.43 loss per share (further deteriorated from kr0.85 loss in FY 2021). Net loss: kr60.2m (loss widened 140% from FY 2021). Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe.
Reported Earnings • Oct 30Third quarter 2022 earnings released: kr0.33 loss per share (vs kr0.54 profit in 3Q 2021)Third quarter 2022 results: kr0.33 loss per share (down from kr0.54 profit in 3Q 2021). Net loss: kr13.3m (down 176% from profit in 3Q 2021). Revenue is forecast to grow 79% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany.
Reported Earnings • Aug 25Second quarter 2022 earnings released: kr0.45 loss per share (vs kr0.60 loss in 2Q 2021)Second quarter 2022 results: kr0.45 loss per share. Revenue: kr24.0k (up 100% from 2Q 2021). Net loss: kr17.9m (loss widened 29% from 2Q 2021).
Reported Earnings • May 13First quarter 2022 earnings released: kr0.36 loss per share (vs kr0.65 loss in 1Q 2021)First quarter 2022 results: kr0.36 loss per share. Revenue: kr53.0k (down 87% from 1Q 2021). Net loss: kr14.2m (loss widened 3.7% from 1Q 2021).
공시 • May 08Sprint Bioscience Launches NIMA at BIO InternationalSprint Bioscience announced its latest development project NIMA. Now the company chooses to shed some more light on the program, revealing the target protein. The official launch will be at BIO International, which this year will be held in San Diego June 13-16.
Board Change • Apr 27High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Director Rune Nordlander is the most experienced director on the board, commencing their role in 2010. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 18Full year 2021 earnings released: kr0.85 loss per share (vs kr2.55 loss in FY 2020)Full year 2021 results: kr0.85 loss per share (up from kr2.55 loss in FY 2020). Revenue: kr35.0m (up 83% from FY 2020). Net loss: kr25.1m (loss narrowed 41% from FY 2020). Over the next year, revenue is expected to shrink by 5.8% compared to a 44% growth forecast for the pharmaceuticals industry in Germany.
Reported Earnings • Feb 17Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: kr0.85 loss per share (up from kr2.55 loss in FY 2020). Revenue: kr35.1m (up 83% from FY 2020). Net loss: kr25.1m (loss narrowed 41% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is expected to shrink by 5.9% compared to a 59% growth forecast for the pharmaceuticals industry in Germany.
Reported Earnings • Oct 29Third quarter 2021 earnings released: EPS kr0.54 (vs kr0.36 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr33.9m (up 399% from 3Q 2020). Net income: kr17.6m (up kr23.6m from 3Q 2020). Profit margin: 52% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue.
공시 • Sep 08Sprint Bioscience AB (publ) Adds New Cancer Drug Program to its Project PortfolioSprint Bioscience AB (publ) announces that the company is broadening its pipeline with an additional drug program for the treatment of solid tumors. The program goes by the program name NIMA and aims to develop drugs to inhibit a naturally occurring protein that is associated with poor survival in several different forms of cancer. An important aspect of the development of a tumor is that the cancer cells can affect their environment to facilitate the growth of the tumor. This environment is called the tumor microenvironment and differs from the environment around the healthy cells in the body. The ability of cancer cells to reprogram the healthy cells present in the tumor facilitates tumor growth and can inhibit the body's immune system. The NIMA program focuses on a target protein that produces metabolites that are important for this reprogramming of the tumor's microenvironment. Sprint Bioscience develops inhibitors of this target protein to restore balance and thereby prevent the growth of cancer cells while increasing the immune system's ability to attack them. High levels of the current target protein have been found in tumors from, amongst others, ovarian cancer, breast cancer, and colorectal cancer. Patients with high levels of this protein have a poorer prognosis.
Reported Earnings • Aug 18Second quarter 2021 earnings released: kr0.60 loss per share (vs kr1.01 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: kr12.0k (down 100% from 2Q 2020). Net loss: kr13.9m (loss widened 11% from 2Q 2020).
Reported Earnings • May 14First quarter 2021 earnings released: kr0.65 loss per share (vs kr0.79 loss in 1Q 2020)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: kr408.0k (down 93% from 1Q 2020). Net loss: kr13.7m (loss widened 40% from 1Q 2020).
공시 • Apr 10Sprint Bioscience AB (publ) announced that it has received SEK 20.713701 million in fundingSprint Bioscience AB (publ) (OM:SPRINT) announced a private placement of 4,061,510 shares at an issue price SEK 5.10 per share for gross proceeds of SEK 20,713,701 on April 8, 2021. The transaction included participation from new and existing investors.
Executive Departure • Mar 03Interim Chief Executive Officer Charlotte Leife has left the companyOn the 1st of March, Charlotte Leife's tenure as Interim Chief Executive Officer of the company ended after less than a year in the role. We don't have any record of a personal shareholding under Charlotte's name. Charlotte is the only executive to leave the company over the last 12 months. Under Charlotte's leadership, the company delivered a total shareholder return of -1.3%.
공시 • Feb 26Sprint Bioscience AB (publ) Appoints Erik Kinnman as New CEO in Place of Charlotte LeifeSprint Bioscience AB (publ) announced that Erik Kinnman has been appointed as new CEO of the company. He has 25 years of experience from leading positions in the pharmaceutical and biotechnology industry. Erik Kinnman will take up the role on March 1 and succeed Charlotte Leife, who has been acting CEO since September 1, 2021. Erik Kinnman was between 2016 and January 2021 CEO of Abliva AB (formerly Neurovive). Prior to that, he held senior positions at AstraZeneca and SOBI and was also active as a financial analyst at Danske Bank.
Is New 90 Day High Low • Feb 21New 90-day low: €0.63The company is down 17% from its price of €0.76 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period.
Analyst Estimate Surprise Post Earnings • Feb 20Revenue beats expectationsRevenue exceeded analyst estimates by 13%. Over the next year, revenue is forecast to grow 62%, compared to a 50% growth forecast for the Biotechs industry in Germany.
Reported Earnings • Feb 19Full year 2020 earnings released: kr2.02 loss per share (vs kr1.92 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: kr19.6m (down 42% from FY 2019). Net loss: kr42.8m (loss widened 99% from FY 2019).
Is New 90 Day High Low • Feb 03New 90-day low: €0.68The company is down 10.0% from its price of €0.76 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period.
Reported Earnings • Nov 02Third quarter 2020 earnings released: kr0.36 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: kr6.79m (up 55% from 3Q 2019). Net loss: kr5.99m (loss narrowed 17% from 3Q 2019).